Effects of red mold dioscorea with pioglitazone, apotentially functional food, in the treatment of diabetes
Journal
Journal of Food and Drug Analysis
Date Issued
2014
Author(s)
Abstract
The prevalence of type 2 diabetes mellitus is increasing rapidly, and its treatment with pioglitazone is likely to induce rhabdomyolysis. We aimed to determine the effect of cotreatment with pioglitazone and red mold dioscorea (RMD) produced by Monascus purpureus NTU 568 on pancreas function in streptozotocin (STZ)-induced diabetic rats. In diabetic rats fed RMD, RMD with pioglitazone, and pioglitazone alone, insulin concentrations increased significantly by 18.6-40.4%, 64.0-100.0%, and 52.8%, respectively, compared with that in the diabetic group (p < 0.05). Oral glucose tolerance was impaired in the STZ-induced diabetic group within 4 weeks, however, oral glucose tolerance in rats treated with RMD or RMD with pioglitazone improved after 4 weeks, 6 weeks, and 8 weeks. Findings from this study might lend support to the use of RMD as a novel functional food for the prevention of diabetes. ? 2015, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan LLC.
Subjects
diabetes; insulin resistance; Monascus purpureus NTU 568; red mold dioscorea; rhabdomyolysis
SDGs
Other Subjects
alanine aminotransferase; alkaline phosphatase; ankaflavin; aspartate aminotransferase; calcium; chloride; cholesterol; creatine kinase; creatinine; glycosylated hemoglobin; high density lipoprotein cholesterol; insulin; lipid; low density lipoprotein cholesterol; monascin; natural product; phosphorus; pioglitazone; potassium; red mold dioscorea; sodium; unclassified drug; animal experiment; animal model; Article; controlled study; diabetes mellitus; electrolyte balance; food safety; functional food; glucose blood level; kidney function; lipid blood level; liver function test; male; Monascus purpureus; nonhuman; oral glucose tolerance test; pancreas function; rat; risk assessment; streptozotocin-induced diabetes mellitus
Type
journal article